29 May 2019 - - US-based pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented KVD900 phase 1 Data at the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary.

KalVista's oral presentation and poster showed that KVD900 rapidly reached high levels of drug exposure and was well tolerated without related gastrointestinal adverse events.

KVD900 successfully interrupts the contact activation system's positive feedback loop between plasma kallikrein, prekallikrein, and FXII.

Within 10 minutes an inhibitory effect on plasma kallikrein activity was detected with KVD900 in undiluted plasma and within 20 minutes it was by greater than 95%.

KVD900 provided critical high molecular weight kininogen cleavage protection for at least 10 hours.

KalVista Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body's inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation.

KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema and diabetic macular edema.

The company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME. The company has selected KVD900 as its programme to be advanced as an on-demand therapy for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE patients in late 2018.

In DME, KalVista's most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that is anticipated to complete in the second half of 2019.